BCPT02  (Synonyms: BLD1102)

BCPT02 (BLD1102) is a Topoisomerase-I inhibitor and ADC payload (ADC Payload). BCPT02 can form the ADC BCG041. BCPT02 is applicable to cancer-related research^[1].

BCPT02 is the topoisomerase I inhibitor payload used in the bispecific antibody-drug conjugate (ADC) BCG041^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

1706.75

C₇₆H₁₁₁N₁₁O₃₃

3025473-38-2

O=C(CCOCC(COCCC(NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=O)(COCCC(NC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)=O)NC(CC[C@H](NC(CCCCCN1C(C=CC1=O)=O)=O)C(N[C@@H](C(C)C)C(N[C@@H](C)C(NC2=CC=C3C4=C2OCCC4=C(CN5C6=O)C(C5=CC([C@@](CC)7O)=C6COC7=O)=N3)=O)=O)=O)=O)NC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Niu I, et al. BCG041: A first-in-class bispecific ADC targeting B7-H3 and the proximal membrane region of MUC1 with superior antitumor activity[J]. Cancer Research, 2026, 86(7_Supplement): 1721-1721.